Who are sibutramine, orlistat, diethylpropion's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sibutramine-orlistat-diethylpropion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

sibutramine, orlistat, diethylpropion — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

sibutramine, orlistat, diethylpropion (sibutramine, orlistat, diethylpropion) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiobesity agents (combination). Area: Obesity / Weight Management.

marketed Antiobesity agents (combination) Norepinephrine transporter, serotonin transporter, pancreatic lipase, sympathomimetic amine receptor Obesity / Weight Management Small molecule Live · refreshed every 30 min

Target snapshot

sibutramine, orlistat, diethylpropion (sibutramine, orlistat, diethylpropion) — Pennington Biomedical Research Center. This is a combination of three distinct weight-loss medications that work through different mechanisms: sibutramine inhibits norepinephrine and serotonin reuptake, orlistat inhibits pancreatic lipase to reduce fat absorption, and diethylpropion is a sympathomimetic amine that suppresses appetite.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
sibutramine, orlistat, diethylpropion TARGET	sibutramine, orlistat, diethylpropion	Pennington Biomedical Research Center	marketed	Antiobesity agents (combination)	Norepinephrine transporter, serotonin transporter, pancreatic lipase, sympathomimetic amine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiobesity agents (combination) class)

Pennington Biomedical Research Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). sibutramine, orlistat, diethylpropion — Competitive Intelligence Brief. https://druglandscape.com/ci/sibutramine-orlistat-diethylpropion. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab